Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remde­sivir; Hahn pleads with pub­lic to trust FDA's vac­cine re­view

A bi­par­ti­san group of 34 at­tor­neys gen­er­al have asked the fed­er­al gov­ern­ment to by­pass Gilead’s patent rights on remde­sivir and be­gin scal­ing and dis­trib­ut­ing the Covid-19 an­tivi­ral, or to al­low the states to do it them­selves.

In a let­ter to HHS sec­re­tary Alex Azar, the AGs ex­pressed frus­tra­tions over the $3,250 price tag Gilead placed on the the drug, cit­ing the fed­er­al fund­ing that went in­to its de­vel­op­ments. And they not­ed the sus­tained dif­fi­cul­ties hos­pi­tals have faced in get­ting sup­plies from ei­ther the Cal­i­for­nia biotech or their con­tract man­u­fac­tur­er Amerisource­Ber­gen.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN